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Background: There is lack of data on prevalence of celiac disease (CD) in children with type 1 diabetes (T1D) in
Arabs in the Middle East. The present investigation aims to study the prevalence rate and clinical characteristics of
CD among Saudi children with T1D using a combination of the most sensitive and specific screening serologic
tests (anti- tissue transglutaminase antibodies IgA [anti-TTG] and ednomyseal antibodies [EMA]) and to determine
the lower cut-off value of anti- anti-TTG level that best predicts CD in children with T1D.
Methods: Children with T1D following in diabetic clinic have been prospectively screened for presence of CD, over
a two-year period (2008–2010), by doing anti-TTG, EMA, and total IgA. Children with positive anti-TTG titres
(>50 U/ml) and/or EMA and children with persistently low positive anti-TTG titres (two readings 20–50 U/ml; within
6 months intervals) had upper endoscopy and 6 duodenal biopsies.
Results: One hundred and six children with T1D have been screened for CD: age ranged between 8 months to 15.5 years
(62 females). Nineteen children had positive anti-TTG and/or EMA, however only 12 children had biopsy proven CD
(11.3%). Five of 12 had gastrointestinal symptoms (42%). Children with T1D and CD had significantly lower serum iron than
children with T1D alone (8.5 μgm/L Vs 12.5 μgm/L; P = 0.014). The sensitivity and specificity of anti-TTG were 91.6% and
93.6%, with a positive and negative predictive value of 64.7% and 98.8%, respectively. Receiver operated characteristics
analysis for the best cut-off value of anti-TTG level for diagnosis of CD was 63 units (sensitivity 100% and specificity 98.8%).
Conclusion: CD is highly prevalent among Saudi children with T1D. Anti-TTG titres more than 3 times the upper limit of
normal has very high sensitivity and specificity for diagnosis of CD in T1D children.
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Type 1 diabetes mellitus (T1D) and celiac disease (CD)
are both autoimmune disorders. In the last two decades,
increased CD prevalence (1–16%) in patients with type 1
diabetes mellitus (T1D) has been well documented in nu-
merous screening studies made all over the world [1–5].
There is limited data on the prevalence of CD in Arab
children with T1D. Data from Arab countries in North
Africa indicate prevalence rate ranging from 5 to 16%* Correspondence: aa_alhussaini@yahoo.com
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distribution, and reproduction in any medium[3,6,7]. There is a limited data on prevalence of CD in chil-
dren with T1D in Arabs in Middle East. Anti-gliadin anti-
bodies-based screening study in Riyadh, the capital city of
Saudi Arabia, revealed a 4.9% prevalence of CD in T1D
children [8]. Anti-gliadin antibodies-based screening is no
longer recommended because of the poor sensitivity and
specificity [9]. In a large retrospective, anti-tissue transglu-
taminase (anti-TTG) antibodies based, screening study,
the prevalence of CD among T1D children in Western re-
gion of Saudi Arabia was 11.2% [10].
Several studies confirmed that high concentrations of
anti-TTG in serum predict villous atrophy better than low
values [11–13]. On the other hand, low anti-TTG values
have low sensitivity and specificity for diagnosis of CD
[14,15]. Children with T1D, like other autoimmune diseasestral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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tive anti-TTG results at low values [16]. Thus children with
T1D and low anti-TTG values might be subjected to
anesthesia and endoscopy un-necessarily. Therefore, deter-
mination of the lower positive cut-off value of anti-TTG
that best predict CD in T1D patients might help in propo-
sing an efficient and economical strategy for diagnosing CD.
The two main aims of the present prospective cross-
sectional study were to study the prevalence rate and
clinical characteristics of CD in Saudi children with T1D
using a combination of the most sensitive and specific
screening serologic tests (Anti-TTG and EMA), and to
determine the lower positive cut-off value of anti-TTG
that best predicts histopathological diagnosis of CD in
children with T1D.
Methods
We prospectively enrolled 106 children with T1DM seen
in the diabetic clinics of the King Saud Medical City,
Riyadh, during the period from June 2008 through January
2010. After explaining the objectives of the study, a writ-
ten informed consent was obtained from the children’s
parents. A physician interviewed parents and performed
physical examination for all enrolled patients. During
interviews, patients and their parents were asked about
persistent gastrointestinal symptoms such as diarrhea,
constipation, abdominal distension, vomiting, and abdo-
minal pain over the past year. Gender of the patients, their
ages, age at onset of diabetes and duration of diabetes
were recorded. Medical chart review focused on results of
other antibody tests such as serum antithyroperoxidase,
associated diseases, and patient’s age at onset of diabetes.
Blood samples were collected for: anti-TTG immuno-
globulin subclass A (IgA) using enzyme linked immune-
sorbent assay (ELISA) and endomyseal antibody (EMA)
IgA subclass using indirect immunofluorescence assay,
total IgA, CBC, Iron profile, glycosylated hemoglobin
(HbA1C), calcium, phosphorus, albumin.
The criterion for selection of patients undergoing in-
testinal biopsy was any of the following:
I. Positive anti-TTG and positive EMA
II. Positive EMA alone
III. Positive anti-TTG > 50 U/ml alone
IV. Persistently positive anti-TTG at low titer 20 – 50
U/ml (two readings in 6 months)
Following endoscopy, if indicated, 6 duodenal biopsies
were obtained including one from duodenal cap. Biop-
sies were immersed in formalin solution and examined
histologically at the Department of Pathology. Formalin-
fixed biopsies were stained with hematoxylin and eosin
and examined under light microscopy. Biopsies were
reviewed by a single pathologist and reported accordingto Marsh classification [17,18]. The pathologist was
blinded to clinical and endoscopic data and serologic
results.
Methods of Serology tests
1) Anti -TTG IgA testing was undertaken with a
commercially obtained ELISA kit (Inova Diagnostics,
San Diego, California, USA). In brief, stored serum
samples were thawed and diluted with horseradish
peroxidase diluent and tested in duplicate at room
temperature along with appropriate negative and
positive controls. The optical density of each pair of
duplicates was converted to an ELISA standard by
reference to positive controls. An ELISA cutoff of
less than 20 was considered normal and greater than
20, positive. Children with low anti-TTG titer
(20–50 U/ml) had a repeat of the test after 6
months. Anti-TTG value < 20 U/ml on the second
test defines transient positivity of Anti-TTG and
deems intestinal biopsy unnecessary. Persistent
positivity of anti-TTG at low titers was considered
an indication for intestinal biopsy.
2) EMA (IgA) in serum was measured using indirect
immunofluorescence assay and cryostat sections of
monkey esophagus (INOVA Diagnostics Inc., San
Diego, California, USA). Serum samples were
incubated with substrate for 30 min in moist chamber;
sections were then washed with phosphate-buffered
saline and incubated for 30 min with fluorescein
isothiocyanate. Finally, after washing and applying the
mounting medium, sections were examined using
fluorescence microscope and the results were reported
by comparing with positive and negative controls
which were included in every assay. The assays were
performed at 3 screening dilutions of 1:5, 1:10, and
1:20. The test result was considered positive when
there was a reticulated honeycomb staining of the
connective tissue that surrounded the bundles of
esophageal smooth muscle.
3) Total IgA: Serum level of IgA had been assayed
using a nephelometric method with the aid of a BN
II nephelometer (Siemens, Germany).
The study was approved by the local research and ethics
committee of Children’s hospital at King Saud Medical
City and had been performed in accordance with the ethi-
cal standards laid down in the 1964 Declaration of
Helsinki.
Statistical analysis
The data were analyzed using SPSS pc+ version 16.0
statistical software. Descriptive statistics (mean, standard
deviation and proportions) were used to summarize the
study variables. Student’s t-test for independent samples
Group 1
+ve anti-TTG and 
+veEMA         
n=11
106 children with type 1 diabetes
Anti-TTG, EMA (IgA) and total IgA level
Group 2




anti-TTG >50 U/ml 
and -ve EMA           
n=4
Group 4
Anti-TTG 20-50 U/ml 
and -ve EMA      
n=10
1 patient refused 
endoscopy 
Biopsy proven CD   n= 9 
negative biopsy     n=1  
Biopsy proven CD 
n= 1










CD= celiac disease; EMA= endomyseal antibody; n= number; Anti-TTG= anti-tissue transglutaminase IgA; -ve= negative; +ve= positive
Figure 1 Flowchart for results of the serologic tests and biopsy proven celiac disease.
Table 1 Results of repeated anti-TTG test in the group
with positive low anti-TTG titer
Patient First anti-TTG
(U/ml)












Anti-TTG= anti-tissue transglutaminase IgA.
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study variables. The 95% confidence intervals for differ-
ence of mean were used. Chi-square test and Fisher’s
exact tests were used to observe an association between
the qualitative study and outcome variables. Sensitivity
and specificity values were calculated to evaluate the
test procedures (EMA & anti-TTG) in comparison with
gold standard (Biopsy). Receiver operated characteristics
(ROC) curve was used to determine the best cut-off
anti-TTG value with best sensitivity and specificity to
diagnose CD. A p value of less than 0.05 was considered
statistically significant.
Results
Of the 106 children screened, 62 were females; age ranged
between 8 months and 15.5 years (Mean 8.5 years ± 2.8
years). Mean age at diagnosis of T1D was 6.3 ± 2.9 years
(range 0.85 – 11 years). Mean time of duration of T1D
was 2.2 ± 2.1 years (range 0 – 8 years).
Serologic screening
Of 106 children with T1D, 26 (24.5%) were positive for
anti-TTG and / or EMA (Figure 1). In group 4, five of 10
patients with positive low anti-TTG titer (20–50 U/ml)
had a negative anti-TTG on a repeated test done after 6
months (Table 1), resulting in overall seroprevalence of
20% (21/106). None of the 10 patients in group 4 had
gastrointestinal symptoms. A total of 21 upper endosco-
pies and duodenal biopsies were performed with 12
patients showing histological features consistent with ce-
liac disease (11.3%) (Figure 1). One patient in group 1refused endoscopy; he had positive anti-TTG 212 U/ml
and positive EMA. The only patient that was EMA and
anti-TTG positive but had a normal biopsy had a low
positive anti-TTG level (29 U/ml) compared with the
other 10 patients with proven atrophic mucosa. Total
serum IgA level was in the normal range in all patients.
The specificity, sensitivity, positive predictive value, and
negative predictive value of the anti-TTG and EMA tests
are shown in Table 2.
Intestinal biopsy proven celiac disease
Clinical, serologic, and histopathological data of 12 chil-
dren with biopsy proven celiac disease are given in Table 3.
Three of 12 patients were diagnosed with CD at time of
Table 2 Sensitivity and specificity of anti-TTG and EMA




Positive predictive value 64.7% 90.9%
Negative predictive value 98.8% 96.8%
T1D= Type 1 diabetes ; Anti-TTG= anti-tissue transglutaminase IgA;
EMA= ednomyseal antibodies.
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intestinal symptoms. Gluten free diet has been initiated in
all 12 children. Table 4 shows comparison of T1D children
with and without celiac disease. Two findings were statisti-
cally significant among celiac group: predominance of
female gender (92% versus 54%, P = 0.014) and iron defi-
ciency (8.5 μmol/L versus 12.5 μmol/L, P= 0.014).
Receiver operated characteristics curve analysis of anti-
TTG values
In order to establish the optimal cut-off / threshold
values of anti-TTG for best sensitivity and specificity for
diagnosis of CD, we have performed ROC curve analysis
by plotting sensitivity against 100-specificity at different
cut-off values of anti-TTG (Figure 2). Anti-TTG value at
62.7 U/ml had 100% sensitivity and 98.8% specificity for
prediction of diagnosis of CD, with area under the ROC
curve of 0.999 and 95% confidence interval of 0.962 to 1
and a significance level of p<0.0001(Area=0.5).
Discussion
The two most important findings of our study are the high
prevalence of CD among Saudi children with T1D (11.3%)Table 3 Clinical and histopathological profile of 12 children w
Patient Age
(year)
Sex Age of onset of T1D
(year)
Age at diagnosis of
(year)
1 7.5 M 7 7
2 9.5 F 3.5 9.5
3 12 F 9 12
4 11 F 10 11
5 10 F 3 10
6 4 F 4 4
7 9.5 F 5 9.5
8 11 F 11 11
9 13 F 7 13
10 9 F 7 9
11 8 F 7 8
12 6.5 F 5.5 6.5
T1DM= Type 1 diabetes; Anti-TTG= anti-tissue transglutaminase IgA; EMA= ednomyand the identification of the lowest positive anti-TTG
value (63 U/ml) that best predicts CD in diabetic children
with a sensitivity of 100% and specificity of 98.8%. World-
wide, prevalence of CD in children with T1D ranges from
1% to 10% [1–5]. Exceptions being Algeria and Argentina
where prevalence rates were reported as 16.4% [19] and
13.9% [20] respectively. Our study identified CD by using
rigorous uniform diagnostic criteria including combin-
ation of two highly sensitive and specific tests (anti-TTG
and EMA), and by performing 6 duodenal biopsies in sus-
pected cases in order to minimize the chance of missing a
case of CD that can occur because of the recognized
patchiness of histopathological changes. Very Few studies
exist in which screening for CD-associated antibodies
includes combination of anti-TTG and EMA [2]. Preva-
lence of CD in our study could have been even higher
(12.2%) if we had obtained consent for small bowel biopsy
in one child with combined anti-TTG and EMA positive
tests. To the best of our knowledge the prevalence rate in
our study group is the highest reported in the Middle East
and Asia. Such a high prevalence could be related to
genetic and environmental factors predisposing to deve-
lopment of CD in Saudi population.
Studies on impact of CD on diabetes control and growth
in children with T1D have shown conflicting results
[21–23]. In the present study, children with CD had dia-
betic control and growth parameters equivalent to chil-
dren without CD. The lack of impact of CD on diabetic
control and growth in our study could be related to the
relative short duration of diabetes (2.7 years ± 2.5) and
that 4 patients were diagnosed with CD at time of diagno-
sis of diabetes. However, our cross-sectional data do not







117 +ve 3-a Diarrhea Abdominal
pain
212 +ve 3-c -
283 +ve 3-b Abdominal pain
236 +ve 3-b -
103 +ve 3-c -
109 +ve 1 -
19 +ve 3-a -
271 +ve 3-c Constipation
Distension
bloating
151 +ve 3-b -
287 +ve 3-c bloating
211 -ve 3-c Abdominal pain
65 -ve 3-a -
seal antibodies.
Table 4 Comparison of T1D children with and without celiac disease
Study variables mean (± SD) Celiac disease p-value
Yes (12) No (94)
Age (year) 9.2 (2.5) 8.5(2.9) 0.38
Age at Diagnosis of T1DM (year) 6.6(2.5) 6.3(3.0) 0.80
Female gender (%) 11(92%) 51 (54%) 0.014*
Duration of T1DM (year) 2.7(2.5) 2.1(2.1) 0.38
Weight(Z-score) 0.04(0.5) −0.005(1.0) 0.88
Height (Z-score) 0.18(0.56) −0.02(1.0) 0.50
HbA1c 11.02(2.3) 10.7(2.5) 0.66
Hemoglobin (gm/dl) 12.5(1.0) 13.1(1.0) 0.08
BMI (%) 16.9(2.5) 16.5(3.6) 0.76
MCV (fl) 75.9(6.9) 79.1(5.1) 0.05
MCH (pg) 25.2(2.6) 26.4(2.0) 0.05
Serum iron (normal 9–30.4 μmol/L) 8.5 (3.7) 12.5(5.4) 0.014*
Serum calcium (normal 2.2 –2.7 mmol/L) 2.3(0.07) 2.3(0.16) 0.61
Autoimmune disease
Yes (%) 2 (16.7) 8(8.5) 0.31
T1DM= Type 1 diabetes; HbA1c= glycoselated hemoglobin; *= statistically significant result, -ve= negative; +ve= positive.
Area under the ROC curve 0.999
Standard Error 0.00144
95% Confidence Interval 0.962 to 1.000
Significance level P (Area=0.5) <0.0001
Anti-TTG 













Figure 2 Receiver operated characteristics curve analysis of anti-TTG values.
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toms, iron deficiency, an index of malabsorption, was
prominent in the CD group, a finding that has been
shown in another study [24]. The potential for early rever-
sal of abnormalities in indices of intestinal malabsorption
(iron and calcium deficiencies) is one of the advantages
for screening asymptomatic children for early detection of
CD in T1D patients. The predominance of female gender
among CD group in the present study has been observed
in few studies [25,26], while other studies in different races
have shown male predominance [27,28], which likely
represents variability of genetic and environmental factors
among different races.
Several studies have shown that there is a positive cor-
relation between level of anti-TTG antibodies and degree
of villous atrophy with high levels of anti-TTG (> 10 times
the upper limit of normal in concentration-dependent
antibody tests based on calibration curves) which predict
villous atrophy better than low values [11–13]. Patients
with positive anti-TTG and normal intestinal biopsy in
our study had a low positive anti-TTG level (20–67.8 U/
ml) compared with the other 11 patients with higher anti-
TTG and proven atrophic mucosa. The low sensitivity and
specificity of low positive anti-TTG values for diagnosis of
CD have also been observed in other studies [14,15,27].
Another finding that has also been observed by others
[16], is that children with T1D, like other autoimmune di-
seases at risk of CD, could have transiently positive anti-
TTG results at low values. Thus children with T1D and
low anti-TTG values might be un-necessarily subjected to
anesthesia and endoscopy. Transient positivity of CD-
specific antibodies in patients with T1D has also been
reported with anti-gliadin antibodies [29,30] but was not
reported with EMA [31].
By performing ROC curve analysis, we identified anti-
TTG value at 62.7 U/ml 3 times the upper limit of
normal to have 100% sensitivity and 99% specificity for
prediction of diagnosis of CD. Our result support the
recommendations by CD working group in European
Society of Pediatric Gastroenterology, Hepatology, and
Nutrition (ESPGHAN) enclosed in the recent guidelines
for the diagnosis of coeliac disease in children and
adolescents [32]. In asymptomatic children with CD-
associated condition (like T1D), the guidelines recom-
mend performance of upper endoscopy and intestinal
biopsies if anti-TTG titres exceeds three times the upper
limit of normal. If anti-TTG titres are low positive, that
is less than three times upper limit of normal, the guide-
lines recommend one of two approaches to avoid un-
necessary biopsies: first, the child may be followed on a
normal gluten containing diet and anti-TTG testing to
be repeated in 3 – 6 monthly intervals; the second op-
tion involves doing EMA and if positive the child should
be referred for intestinal biopsies [32].Conclusion
The prevalence rate of CD among Saudi children with
T1D is among the highest in the world. Anti-TTG titres
more than 3 times the upper limit of normal has very
high sensitivity and specificity for diagnosis of CD in
T1D children. In order to support the latter finding, lar-
ger prospective studies are needed.Abbreviations
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